'Activation-induced cell death': A special program able to preserve the homeostasis of the skin?

Experimental Dermatology

Volumn 11, Issue 1, 2002, Pages 1-11

  De Panfilis, Giuseppe ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Activation induced cell death; Cell suicide; Fas Fas L; Skin diseases

Indexed keywords

DRUG; FAS ANTIGEN; FAS LIGAND; ANTIGEN;

ACTIVATION INDUCED CELL DEATH; ALOPECIA AREATA; APOPTOSIS; ATOPIC DERMATITIS; BIOCHEMISTRY; CELL DAMAGE; CELL KILLING; CELL SURVIVAL; CUTANEOUS T CELL LYMPHOMA; DRUG INDUCED DISEASE; ERYTHEMA MULTIFORME; HOMEOSTASIS; HUMAN; INFLAMMATORY CELL; KERATINOCYTE; LICHEN PLANUS; LICHENOID; LYMPHOCYTIC INFILTRATION; MELANOGENESIS; MELANOMA; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SKIN; SKIN CARCINOMA; SKIN DISEASE; SKIN INFLAMMATION; SKIN MANIFESTATION; SKIN TUMOR; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; ULTRAVIOLET RADIATION; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; T LYMPHOCYTE;

ANTIGENS; HOMEOSTASIS; HUMANS; LYMPHOCYTE ACTIVATION; SKIN DISEASES; SKIN PHYSIOLOGY; T-LYMPHOCYTES;

EID: 0036482226     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0625.2002.110101.x     Document Type: Review

References (121)

1. Teraki Y, Shiohara T. Apoptosis and the skin. Eur J Dermatol 1999: 9: 413-426.
2. Wehrli P, Viard I, Bullani R, Tschopp J, French LE. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000: 115: 141-148.
3. Weedon D. Apoptosis. Adv Dermatol 1990: 5: 243-256.
4. Paus RT, Rosenback T, Haas N, Czarnetzki BM. Patterns of cell death: The significance of apoptosis for dermatology. Exp Dermatol 1993: 2: 3-11.
5. Raskin CA. Apoptosis and cutaneous biology. J Am Acad Dermatol 1997: 36: 885-896.
6. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993: 14: 338-339.
7. Nagata S. Apoptosis by death factor. Cell 1997: 88: 355-365.
8. De Panfilis G, Caruso A, Sansoni P, Pasolini G, Semenza D, Torresani C. Identification of Fas-L-expressing apoptotic T lymphocytes in normal human peripheral blood: 'In vivo' suicide. Am J Pathol 2001: 158: 387-391.
9. Russell JH, Rush B, Weaver C, Wang R. Mature T cells of autoimmune 1pr/1pr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA 1993: 90: 4409-4413.
10. Russell JH, Wang R. Autoimmune gld mutation uncouples suicide and cytokine/proliferative pathways in activated mature T cells. Eur J Immunol 1993: 23: 2279-2382.
11. Adachi M, Suematsu S, Kondo T et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995: 11: 294-300.
12. + T cells in vivo. J Immunol 1999: 163: 3138-3142.
13. Van Der Burg M, De Groot R, Comans-Bitter WM et al. Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: A dominant or recessive disease? Pediatr Res 2000: 47: 336-343.
14. Bader-Meunier B, Rieux-Laucat F, Croisille L et al. Dyserythropoiesis associated with a fas-deficient condition in childhood. Br J Haematol 2000: 108: 300-304.
15. Bleesing JJ, Straus SE, Fleisher TA. Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 2000: 17: 1291-1310.
16. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacboson MD. Programmed cell death and the control of cell survival: Lessons from the nervous system. Science 1993: 262: 695-700.
17. Nagata S, Golstein P. The Fas death factor. Science 1995: 267: 1449-1456.
18. Osborne BA. Apoptosis and the maintenance of homeostasis in the immune system. Curr Opin Immunol 1996: 8: 245-254.
19. Alderson MR, Armitage RJ, Maraskovsky E et al. Fas trasduces activation signals in normal human T lymphocytes. J Exp Med 1993: 178: 2231-2235.
20. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/ (Fas/CD95). Nature 1995: 373: 438-441.
21. Ju ST, Panka DJ, Cui H et al. Fas (CD95) /FasL interactions required for programmed cell death after T-cell activation. Nature 1995: 373: 444-448.
22. Brunner T, Mogil RJ, La Face D et al. Cell-autonomous Fas (CD95) /Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995: 373: 441-444.
23. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998: 4: 31-36.
24. Su X. Autocrine and paracrine apoptosis are mediated by differential regulation of Fas ligand activity in two distinct Jurkat T cell populations. J Immunol 1998: 160: 5288-5293.
25. Brunner T, Mueller C. Is autoimmunity coming to a Fas (t) end? Nat Med 1999: 5: 19-20.
26. Musci MA, Latinis KM, Korezky GA. Signaling events in T lymphocytes leading to cellular activation or programmed cell death. Clin Immunol Immunopathol 1997: 83: 205-222.
27. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: Gene structure, chromosomal location and species specificity. Int Immunol 1994: 6: 1567-1574.
28. Hodge MR, Ranger AM, De La Brouse FC, Hoey T, Grusby MJ, Glimcher LH. Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice. Immunity 1996: 4: 397-405.
29. L. Immunity 1995: 3: 87-98.
30. Noel PJ, Boise LH, Green JM, Thompson CB. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996: 156: 636-642.
31. Radvanyi LG, Shi Y, Homayoun V et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 1996: 156: 1788-1798.
32. Streilein JW. Lymphocyte traffic, T-cell malignancies and the skin. J Invest Dermatol 1978: 71: 167-171.
33. Bos JD, Zonneveld I, Das PK, Krieg SR, Van Der Loos CM, Kapsenberg ML. The skin immune system (SIS): Distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol 1987: 88: 569-573.
34. De Panfilis G, Pasolini G, Marcelli M, Torresani C. CD95-ligand (Fas-L)-expressing epidermal lymphocytes. Br J Dermatol 2000: 143: 892-893.
35. Nickoloff BJ, Schroder JM, Von Den Driesch P et al. Is psoriasis a T-cell disease? Exp Dermatol 2000: 9: 359-375.
36. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999: 140: 1-7.
37. Voorhees JJ. Psoriasis - An immunological disease. J Dermatol 1996: 23: 851-857.
38. Norris DA, Travers JB, Leung DYM. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 1997: 109: 1-4.
39. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992: 126: 1-9.
40. Leung DYM, Travers JB, Norris DA. The role of super-antigens in skin disease. J Invest Dermatol 1995: 105: 378-428.
41. β13.1 genes. Proc Natl Acad Sci USA 1994: 91: 9282-9286.
42. Sato K, Nagayama H, Enomoto M, Tadokoro K, Juji T, Takahashi TA. Autocrine activation-induced cell death of T cells by human peripheral blood monocyte-derived CD4+ dendritic cells. Cell Immunol 2000: 199: 115-125.
43. Murphy FP, Coven TR, Burack LH et al. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis. Arch Dermatol 1999: 135: 1495-1502.
44. Krueger JG, Wolfe JT, Tsukifuji Nabeya R et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995: 182: 2057-2068.
45. Ozawa M, Ferenczi K, Kikuchi T et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999: 189: 711-718.
46. Morita A, Werfel T, Stege H et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997: 186: 1763-1768.
47. Waring P, Müllbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 1999: 77: 312-317.
48. Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB. Fas ligand: A sensor for DNA damage critical in skin cancer etiology. Science 1999: 285: 898-900.
49. Gutierrez-Steil C, Wrone-Smith T, Sun X, Krueger JG, Coven T, Nickoloff BJ. Sunlight-induced basal carcinoma tumor cells and ultraviolet B-irradiated psoriatic plaques express Fas ligand (CD95L). J Clin Invest 1998: 101: 33-39.
50. Friesen C, Herr I, Krammer PH et al. Involvement of the CD95 (Apo1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996: 2: 574-579.
51. Wrone-Smith T, Johnson T, Nelson B et al. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes. Am J Pathol 1995; 146: 1079-1088.
52. + allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991: 97: 389-394.
53. Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute vs. chronic atopic dermatitis. J Clin Invest 1994; 94: 870-876.
54. Leung DYM. Atopic dermatitis: The skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995: 96: 302-318.
55. Oberg HH, Lengl-Janßen B, Kabelitz D, Janssen O. Activation-induced T cell death: Resistance or susceptibility correlated with cell surface Fas ligand expression and T helper phenotype. Cell Immunol 1997: 181: 93-100.
56. Ramsdell F, Seaman MS, Miller RE, Picha KS, Kennedy MK, Lynch DH. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol 1994; 6: 1545-1553.
57. + T-cell clones with different T-helper phenotypes: Role of CD95/CD95L interactions. Blood 1997: 89: 558-569.
58. Vignola AM, Chanez P, Chiappara G et al. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol 1999: 103: 563-573.
59. Yudate T, Yamada H, Tezuka T. Role of staphylococcal enterotoxins in pathogenesis of atopic dermatitis: Growth and expression of T cell receptor-beta of peripheral blood mononuclear cells stimulated by enterotoxins A and B. J Dermatol Sci 1996: 13: 63-70.
60. Campbell DE, Kemp AS. Proliferation and production of interferon-gamma (IFN-gamma) and IL-4 in response to Staphylococcus aureus and staphylcoccal superantigen in childhood atopic dermatitis. Clin Exp Immunol 1997: 107: 392-397.
61. Tanka M, Suda T, Haze K et al. Fas ligand in human serum. Nat Med 1996: 2: 317-322.
62. Konig B, Neuber K, Konig W. Responsiveness of peripheral blood mononuclear cells from normal and atopic donors to microbial superantigens. Int Arch Allergy Immunol 1995: 106: 124-133.
63. Yoshino T, Asada H, Sano S et al. Impaired responses of peripheral blood mononuclear cells to staphylococcal superantigen in patients with severe atopic dermatitis: A role of T cell apoptosis. J Invest Dermatol 2000: 114: 281-288.
64. Lonati A, Licenziati S, Canaris AD et al. Reduced production of both Th1 and Tc1 lymphocyte subsets in atopic dermatitis (AD). Clin Exp Immunol 1999; 115: 1-5.
65. Giannetti A, Pastore S, Girolomoni G. Immunologic aspects of atopic dermatitis. Int J Immunopathol Pharmacol 1997: 10: 123-125.
66. Bos JD, Kapsenberg ML, Sillevis Smitt JH. Pathogenesis of atopic eczema. Lancet 1994: 343: 1338-1341.
67. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity. Cell 1990; 63: 1249-1256.
68. Rocha B, Von Boehmer H. Peripheral selection of the T cell repertoire. Science 1991: 251: 1225-1230.
69. + peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur J Immunol 1991; 21: 1963-1966.
70. McCormack JE, Callahan JE, Kappler J, Marrack PC. Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol 1993: 150: 3785-3792.
71. Webb SR, Hutchinson J, Hayden K, Sprent J. Expansion/deletion of mature T cells exposed to endogenous superantigens in vivo. J Immunol 1994: 152: 586-597.
72. + T cell population bearing a distinctive β chain in MRL lpr/lpr mice suggests a role for the fas protein in peripheral T cell selection. Eur J Immunol 1994: 24: 2761-2766.
73. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994: 1: 365-371.
74. Watanabe D, Suda T, Hashimoto H, Nagata S. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J 1995: 14: 12-18.
75. Chu JL, Ramos P, Rosendorff A et al. Massive upregulation of Fas ligand in lpr and gld mice: Implications for Fas regulation and the graft-versus-host disease-like Wasting syndrome. J Exp Med 1995: 181: 393-398.
76. Khoury EL, Price VH, Greenspan HS. HLA-DR expression by hair follicle keratinocytes in alopecia areata: Evidence that it is secondary to the lymphoid infiltration. J Invest Dermatol 1988: 90: 192-200.
77. MacDonald-Hull S, Nutbrown M, Pepall L, Thornton MJ, Randall VA, Cunliffe WJ. Immunohistologic and ultrastructural comparison of the dermal papilla and hair follicle bulb from 'active' and 'normal' areas of alopecia areata. J Invest Dermatol 1991: 96: 673-681.
78. Bodemer C, Peuchmaur M, Fraitaig S, Chatenoud L, Brousse N, De Prost Y. Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol 2000; 114: 112-116.
79. Kalish R, Johnson K, Hordinsky M. Alopecia areata. Autoreactive T cells are variably enriched in scalp lesions relative to peripheral blood. Arch Dermatol 1992: 128: 1072-1077.
80. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS. Alopecia areata transferred to human scalp explants on SCID mice with T lymphocyte injections. J Clin Invest 1998: 101: 62-67.
81. Gilhar A, Shalaginov R, Assy B, Serafimovich S, Kalish RS. Alopecia areata is a T-lymphocyte mediated autoimmune disease: Lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. J Invest Dermatol Symp Proc 1999; 4: 207-210.
82. Weedon A. Apoptosis in lichen planus. Clin Exp Dermatol 1980: 5: 425-430.
83. Shiohara T, Moriya N, Tanaka Y et al. Immunopathologic study of lichenoid skin disease: Correlation between HLA-DR-positive keratinocytes or Langerhans cells and epidermotropic T cells. J Am Acad Dermatol 1988: 18: 67-74.
84. De Panfilis G. The pathogenesis of lichen planus. Am J Dermatopathol 1987: 9: 362-363.
85. Shiohara T, Moriya N, Nagashima M. The lichenoid tissue reaction: A new concept of pathogenesis. Int J Dermatol 1988: 27: 365-374.
86. Shiohara T, Moriya N, Nagashima M. Induction and control of lichenoid tissue. Springer Semin Immunopathol 1992: 13: 369-385.
87. Gomes MA, Schmitt DS, Souteyrand P, Ohrt C, Brochier J, Thivolet J. Lichen planus and chronic graft-versus-host reaction. In situ identification of immunocompetent cell phenotypes. J Cutan Pathol 1982: 9: 249-257.
88. De Panfilis G, Manara GC, Ferrari C, Manfredi G, Allegra F. Imbalance in phenotypic expression of T cell subpopulations during different evolution stages of lichen planus lesions. Acta Dermatovenereol (Stockholm) 1983: 63: 369-375.
89. De Panfilis G, Manara G, Sansori P, Allegra F. T-cell infiltrate in lichen planus. Demonstration of activated lymphocytes using monoclonal antibodies. J Cutan Pathol 1983: 10: 52-58.
90. Kilpi AM. Activation marker analysis of mononuclear cell infiltrates of oral lichen planus in situ. Scand J Dent Res 1987: 95: 174-180.
91. De Panfilis G. CD8+ cytolytic T lymphocytes and the skin. Exp Dermatol 1998: 7: 121-131.
92. Shimizu M, Higaki Y, Higaki M, Kawashima M. The role of granzyme-B expressing CD8-positive T cells in apoptosis of keratinocytes in lichen planus. Arch Dermatol Res 1997: 289: 527-532.
93. Sugerman PB, Satterwhite K, Bigby M. Autocytotoxic T-cell clones in lichen planus. Br J Dermatol 2000: 142: 449-456.
94. Zhou XJ, Savage NW, Sugermann PB et al. TCR Vβ gene expression in lesional T lymphocyte cell lines in oral lichen planus. Oral Dis 1996: 2: 295-298.
95. Schnyder B, Frutig K, Mauri-Hellweg D, Limat A, Yawalkar N, Pichler WJ. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp All 1998: 28: 1412-1417.
96. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1997: 133: 845-849.
97. Reich K, Brinck U, Letschert M et al. Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol 1999: 141: 739-746.
98. Cohen JJ. Apoptosis: Mechanisms of life and death in the immune system. J Allergy Clin Immunol 1999: 103: 548-554.
99. Thestrup PK, Kaltoft K. Genotraumatic T cells and cutaneous T-cell lymphoma. A causal relationship? Arch Dermatol Res 1994: 287: 97-101.
100. Burg G, Kempf W, Haeffne AC et al. Cutaneous lymphomas. Curr Problems 1997: 9: 137-204.
101. Li G, Chooback L, Wolfe JT et al. Overexpression of p53 protein in cutaneous T cell lymphoma: Relationship to large cell transformation and disease progression. J Invest Dermatol 1998: 110: 767-770.
102. Qin JZ, Dummer R, Burg G, Dobbeling U. Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun and novel Myc-like proteins in cutaneous T-cell lymphoma cells. Blood 1999: 93: 260-267.
103. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998: 92: 252-258.
104. Dereure O, Llanos F, Portales P, Clot J, Guilhou JJ. Normal serum levels of soluble forms of Fas and Fas ligand in patients with cutaneous T cell lymphoma. J Invest Dermatol 2000: 115: 570.
105. Hug H. Fas-mediated apoptosis in tumor formation and defense. Biol Chem 1997: 378: 1405-1412.
106. Xerri L, Devilard E, Hassoun J, Haddad P, Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 1997: 11: 1868-1877.
107. Paulli M, Berti E, Boveri E et al. Cutaneous CD30+ lymphoproliferative disorders: Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998: 29: 1223-1230.
108. Mori M, Manuelli C, Pimpinelli N et al. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. Blood 1999: 94: 3077-3083.
109. Levi E, Wang Z, Petrogiannis-Haliotis T et al. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: A possible mechanism for disease progression. J Invest Dermatol 2000: 115: 1034-1040.
110. Echchakir H, Bagot M, Dorothee G et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 2000: 115: 74-80.
111. Henseleit U, Zhang J, Wanner R, Hasse I, Kolde G, Rosenbach T. Role of p53 in UVB-induced apoptosis in human HaCaT keratinocytes. J Invest Dermatol 1997: 109: 722-727.
112. Leverkus M, Yaar M, Gilchrest BA. Fas/Fas ligand contributes to UV-induced apoptosis in human keratinocytes. Exp Cell Res 1997: 232: 255-262.
113. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998: 1: 543-551.
114. Gniadecki R, Hansen M, Wulf HC. Two pathways for induction of apoptosis by ultraviolet radiation in cultured human keratinocytes. J Invest Dermatol 1997: 109: 163-169.
115. Oishi M, Maeda K, Sugiyama S. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines. Arch Dermatol Res 1994: 286: 396-407.
116. Buechner SA, Werni M, Harr T, Hahn S, Itin P, Erb P. Regression of basal cell carcinoma by intralesional interferon-alpha treatments is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997: 100: 2691-2696.
117. Viard I, Saurat JH, Tschopp J, French LE. Nitric oxide induces Fas-L expression and Fas-mediated apoptosis in HaCaT cells. J Invest Dermatol 2000: 115: 546.
118. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998: 282: 490-493.
119. Aragane Y, Maeda A, Cui CY, Tezuka T, Kaneda Y, Schwarz T. Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo. J Invest Dermatol 2000: 115: 1008-1014.
120. Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition. J Immunol 1999: 162: 3273-3279.
121. Bos JD. The skin as an organ of immunity. Clin Exp Immunol 1997: 107: 3-5.